JP6401702B2 - 炎症性肝疾患の診断のための方法および組成物 - Google Patents

炎症性肝疾患の診断のための方法および組成物 Download PDF

Info

Publication number
JP6401702B2
JP6401702B2 JP2015530512A JP2015530512A JP6401702B2 JP 6401702 B2 JP6401702 B2 JP 6401702B2 JP 2015530512 A JP2015530512 A JP 2015530512A JP 2015530512 A JP2015530512 A JP 2015530512A JP 6401702 B2 JP6401702 B2 JP 6401702B2
Authority
JP
Japan
Prior art keywords
level
control
subject
mdc
psc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015530512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534636A (ja
JP2015534636A5 (enExample
Inventor
ランディ，アブドラミール
ホートン，マイケル
ティレル，ローン，ディー
ランキシュ，ティム
ベイスミューラー，トビアス
マンス，ミヒャエル
Original Assignee
ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ
ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ
メディツィニッシュ ホホシュール ハノーバー
メディツィニッシュ ホホシュール ハノーバー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ, ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ, メディツィニッシュ ホホシュール ハノーバー, メディツィニッシュ ホホシュール ハノーバー filed Critical ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ
Publication of JP2015534636A publication Critical patent/JP2015534636A/ja
Publication of JP2015534636A5 publication Critical patent/JP2015534636A5/ja
Application granted granted Critical
Publication of JP6401702B2 publication Critical patent/JP6401702B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Primary Health Care (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
JP2015530512A 2012-09-07 2013-09-06 炎症性肝疾患の診断のための方法および組成物 Expired - Fee Related JP6401702B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698412P 2012-09-07 2012-09-07
US61/698,412 2012-09-07
US201261718134P 2012-10-24 2012-10-24
US61/718,134 2012-10-24
PCT/IB2013/002611 WO2014037811A2 (en) 2012-09-07 2013-09-06 Methods and compositions for diagnosis of inflammatory liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018170224A Division JP2019012077A (ja) 2012-09-07 2018-09-12 炎症性肝疾患の診断のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2015534636A JP2015534636A (ja) 2015-12-03
JP2015534636A5 JP2015534636A5 (enExample) 2016-10-20
JP6401702B2 true JP6401702B2 (ja) 2018-10-10

Family

ID=50237710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015530512A Expired - Fee Related JP6401702B2 (ja) 2012-09-07 2013-09-06 炎症性肝疾患の診断のための方法および組成物
JP2018170224A Pending JP2019012077A (ja) 2012-09-07 2018-09-12 炎症性肝疾患の診断のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018170224A Pending JP2019012077A (ja) 2012-09-07 2018-09-12 炎症性肝疾患の診断のための方法および組成物

Country Status (7)

Country Link
US (3) US9535071B2 (enExample)
EP (1) EP2893343B1 (enExample)
JP (2) JP6401702B2 (enExample)
CN (1) CN104797933A (enExample)
CA (1) CA2883711A1 (enExample)
HK (1) HK1212448A1 (enExample)
WO (1) WO2014037811A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
US20150278726A1 (en) * 2014-03-31 2015-10-01 James Gelsin Marx Systems and methods for workflow processing
EP3349785A1 (en) * 2015-09-16 2018-07-25 Herlev Hospital Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof
CN106153893B (zh) * 2016-06-14 2018-01-16 浙江大学 唾液抗线粒体抗体m2型的酶联免疫检测试剂盒
US11612888B2 (en) * 2017-01-04 2023-03-28 The Research Foundation For The State University Of New York Biomarker detection device
JP6924600B2 (ja) * 2017-04-10 2021-08-25 シスメックス株式会社 測定方法、測定装置、プログラム、演算式の取得方法および定性判定結果の表示方法
US11719694B2 (en) 2017-10-11 2023-08-08 The Governors Of The University Of Alberta Biomarkers in autoimmune liver disease
CN108931517A (zh) * 2018-07-16 2018-12-04 台州市第人民医院 白介素31在制备原发性胆汁性胆管炎诊断试剂或试剂盒中的应用
CA3123290A1 (en) * 2018-12-26 2020-07-02 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
US20230237649A1 (en) * 2020-04-15 2023-07-27 Children's Hospital Medical Center Systems and Methods for Quantification of Liver Fibrosis with MRI and Deep Learning
CN115287285B (zh) * 2022-03-23 2025-03-11 中国人民解放军总医院第五医学中心 微小核糖核酸miR-126-3p及其应用
WO2024216160A1 (en) * 2023-04-14 2024-10-17 Arc Research Institute Methods and compositions for using peli2 as a biomarker
CN118039132A (zh) * 2024-03-29 2024-05-14 四川大学 基于外观正常牙龈活检信息的大疱性疾病诊断装置及设备

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US20020042096A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20050053938A1 (en) 2001-11-27 2005-03-10 Kohler Rainer H. Regulation of human serine/threonine protein kinase
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
EP1520016A1 (en) 2002-06-28 2005-04-06 Bayer HealthCare AG Human receptor tyrosine kinase mertk
DE60333306D1 (de) 2002-08-30 2010-08-19 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
EP1604011A4 (en) 2003-01-21 2009-12-09 Ptc Therapeutics Inc METHODS FOR IDENTIFYING COMPOUNDS THAT MODULATE THE EXPRESSION OF DEPENDENT GENES FROM A NON-TRANSLATED REGION, AND METHODS OF USING SAME
DE602004030586D1 (de) 2003-09-15 2011-01-27 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
EP1723178A4 (en) 2004-03-12 2007-12-12 Human Genome Sciences Inc HUMAN G-PROTEIN CHEMOKIN RECEPTOR (CCR5) HDGNR10
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
WO2006001011A1 (en) 2004-06-24 2006-01-05 Yissum Research Development Company Use of mycobacterial mannosylated lipoglycans peptide mimotopes for treating inflammation
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
WO2007038749A2 (en) 2005-09-28 2007-04-05 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20110034396A1 (en) 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
EP2046385B1 (en) 2006-07-03 2015-03-25 Charles David Adair Composition for modulating the expression of cell adhesion molecules
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
KR20090035707A (ko) 2006-07-19 2009-04-10 더 오하이오 스테이트 유니버시티 리서치 파운데이션 선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도
EP2610244A1 (en) 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
BRPI0718225A2 (pt) 2006-10-05 2013-11-12 Centocor Ortho Biotech Inc Antagonistas de ccr2 para tratamento de fibrose
MX2009003583A (es) * 2006-10-06 2009-04-15 Nestec Sa Composiciones y ensayos multiples para medir mediadores biologicos de la salud fisiologica.
JP2010509234A (ja) 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US20090118503A1 (en) 2007-06-20 2009-05-07 Kevin Sprott Faah inhibitors
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG191625A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
CN104829718A (zh) 2008-07-08 2015-08-12 艾伯维公司 前列腺素e2结合蛋白及其用途
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
RU2011127198A (ru) 2008-12-04 2013-01-10 Эбботт Лэборетриз Иммуноглобулины с двойными вариабельными доменами и их применение
AU2010242840B2 (en) 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ596711A (en) 2009-05-01 2013-11-29 Dual variable domain immunoglobulins and uses thereof
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
CN102612524A (zh) 2009-09-01 2012-07-25 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
PH12012500691A1 (en) 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2499493A1 (en) * 2009-11-14 2012-09-19 F. Hoffmann-La Roche AG Biomarkers for predicting rapid response to hcv treatment
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease

Also Published As

Publication number Publication date
US10641780B2 (en) 2020-05-05
JP2019012077A (ja) 2019-01-24
HK1212448A1 (en) 2016-06-10
JP2015534636A (ja) 2015-12-03
US20170153251A1 (en) 2017-06-01
US20180209992A1 (en) 2018-07-26
US20150219664A1 (en) 2015-08-06
EP2893343A4 (en) 2016-08-31
CN104797933A (zh) 2015-07-22
CA2883711A1 (en) 2014-03-13
EP2893343B1 (en) 2019-11-20
WO2014037811A2 (en) 2014-03-13
US9535071B2 (en) 2017-01-03
EP2893343A2 (en) 2015-07-15
WO2014037811A3 (en) 2014-05-01
US9952226B2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
JP6401702B2 (ja) 炎症性肝疾患の診断のための方法および組成物
US20130115232A1 (en) Methods for detecting graft-versus-host disease
TWI868698B (zh) 用於快速診斷川崎病的分子生物標誌物和分析方法
CN105021827B (zh) 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
CN116287207B (zh) 生物标志物在诊断心血管相关疾病中的应用
WO2023234422A1 (ja) 三次リンパ組織の検査方法、及び三次リンパ組織の検査用キット
JP6876301B2 (ja) 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
WO2019075109A1 (en) BIOMARKERS IN AUTOIMMUNE HEPATIC DISEASE
US20250130237A1 (en) Point of Care Assays
Macias et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus‐coinfected patients
US20200209242A1 (en) Cancer diagnosis using ki-67
CN112695088A (zh) 标志物、检测试剂、检测产品和诊断系统
CN112695089A (zh) 联合诊断标志物
CN112553332A (zh) 多个基因在肝癌诊断中的联合应用
CN116773825B (zh) 诊断急性川崎病的血液生物标志物和方法
WO2024261762A2 (en) Liver fibrosis, nash and "at-risk" nash biomarkers and methods
US20220196674A1 (en) Treatment of autoimmune liver disease
WO2026016622A1 (zh) 免疫相关不良反应标志物及试剂盒
CN112522402A (zh) 基因标志物的诊断用途
CN112501300A (zh) 用于癌症诊断的分子标志物
CN112695091A (zh) 一种肝脏疾病的诊断系统
CN112695092A (zh) 用于判断患病风险的诊断系统
CN112695093A (zh) 基因组合在诊断肝癌中的用途
US20120301879A1 (en) Novel use of ca-125

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180907

R150 Certificate of patent or registration of utility model

Ref document number: 6401702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees